Biphasic effects of SGLT-2 inhibitors on sleep quality in older people with type 2 diabetes: A longitudinal analysis
Authors' conclusion
SGLT-2 inhibitors cause transient sleep disturbances, likely due to nocturia, but long-term metabolic improvements contribute to recovery. Patients should be informed of temporary sleep changes, and fluid intake should be optimized. Longer studies with objective sleep assessments are needed.
Study context
- Population
- Older adults (≥60 years) with T2D initiating SGLT2i; patients starting sedative medication excluded
- Participants
- 139 adults
- Outcome
- Sleep quality by Pittsburgh Sleep Quality Index (PSQI)
- Follow-up
- Baseline, 1st and 3rd month
Methodological detailslongitudinal
- Longitudinal
Main finding
As reported in the abstract
Mean Pittsburgh Sleep Quality Index (PSQI) at baseline
4.99 ± 2.30
Mean PSQI at 1st month (worsened sleep quality), p vs baseline
6.96 ± 2.41
p < 0.001
Mean PSQI at 3rd month (improved, returning to baseline), p vs 1st month
4.89 ± 2.03
p < 0.001 vs. 1st month
Observational data: associations, not effects.
Further findings
Nocturia-related disturbances
- Nocturia-related disturbances worsened initially but later improved
HbA1c and sleep · 1st and 3rd month
- Higher HbA1c linked to poorer sleep at 1st month
- P = 0.014
- Improved glycaemic control correlated with better sleep at 3rd month
- P = 0.014
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →